Swiss biotech Santhera has raised CHF 22 million ($23.5 million) in bridge financing that it says will allow it to fund its operations through to October, when the FDA is
Santhera has completed a rolling application for its Duchenne muscular dystrophy (DMD) therapy vamorolone in the US, setting up a possible approval and launch in the latter half of 2023.
Being diagnosed with a rare disease is often a bolt from the blue, and while each person’s journey is different, there are common challenges that bind patient communities together.
When he was first told he had LHON, a rare genetic disease that would rob him of his sight, James Ferguson’s first thought was that it would also rob him of his identity.
The latest crop of financings in the digital health category includes a sizeable $84 million round for Wellvana Health, with Genialis, ThoughtFull, and Mindset Health also